Misyo (Methadone Hydrochloride)

Methadone, the active ingredient in Misyo, is an opioid presented as an oral formulation for oral use. It is used to treat opioid dependence and manage chronic pain in adult patients. GNH USA supplies Misyo as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Methadone is employed in the management of opioid‑related disorders and pain, acting on central nervous system opioid receptors. - Opioid dependence: helps maintain stable opioid levels and reduces cravings. - Opioid withdrawal: alleviates withdrawal symptoms during detoxification. - Chronic pain: provides long‑acting analgesia for severe, persistent pain.

Methadone may cause a range of adverse reactions, varying from mild to severe. Common Side Effects: - Nausea: upset stomach and possible vomiting. - Constipation: reduced bowel movements requiring monitoring. - Sweating: excessive perspiration, especially at higher doses. - Drowsiness: feeling unusually sleepy or fatigued. Serious or Rare Side Effects: - Respiratory depression: slowed breathing that can be life‑threatening. - QT interval prolongation: cardiac rhythm changes that may lead to arrhythmia. - Severe hypotension: marked drop in blood pressure causing dizziness or fainting.

When prescribing methadone, clinicians should consider several safety measures to minimize risk. - Assess patient history: evaluate prior opioid use, tolerance, and comorbid conditions. - Monitor respiratory function: watch for depression, especially during initiation or dose changes. - Avoid use in severe hepatic impairment: liver dysfunction can increase drug levels. - Pregnancy considerations: use only if benefits outweigh potential risks to the fetus. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Methadone can interact with other medicines, altering its effects or increasing toxicity. Major Interactions (Avoid): - CNS depressants: may cause profound respiratory depression. - QT‑prolonging agents: increase risk of cardiac arrhythmia. - CYP3A4 inhibitors: can raise methadone plasma concentrations. Moderate Interactions (Monitor Closely): - CYP3A4 inducers: may reduce methadone effectiveness. - Serotonergic drugs: risk of serotonin syndrome when combined.